Corbus Pharmaceuticals appoints Yong Ben, M.D., MBA to Board of Directors

Corbus Pharmaceuticals Holdings, Inc.

Dr. Ben appointed to board effective March 1, 2023; press release issued March 6, 2023.
He brings over 20 years of oncology drug development experience, including roles at BeiGene, BioAtla, and AstraZeneca.
Initial option grant of 5,307 shares; annual cash retainer of $40,000 and annual stock option grant.
Company also entered into standard indemnification agreement with Dr. Ben.
Appointment supports Corbus' precision oncology pipeline including CRB-701 and CRB-601.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Yong Ben

member of the Board

CRBP · Corbus Pharmaceuticals Holdings, Inc.

Effective: 2023-03-01
Filed: March 6, 2023, 6:59 PM ET

On March 1, 2023, the Board of Directors (the “Board”) of Corbus Pharmaceuticals Holdings, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Yong Ben, M.D., MBA, age 49, to serve as a member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Yong Ben was appointed as member of the Board at Corbus Pharmaceuticals Holdings, Inc..

Action: appointed
Role: member of the Board

Exact text from the filing

On March 1, 2023, the Board of Directors (the “Board”) of Corbus Pharmaceuticals Holdings, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Yong Ben, M.D., MBA, age 49, to serve as a member of the Board.

View on SEC.gov

Corbus Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-006132

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.